Separate (Asynchronous) Therapeutic Plasma Exchange (TPE) and Plasma Transfusion in the Patient with Severe TPE Complications: A Case Report
,
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a medical condition characterized by a decreased activity of the ADAMTS13 protease, responsible for cleaving the von Willebrand factor. It contributes to thrombotic microangiopathy. In this report, we described a case of TTP followed by significant adverse effects during therapeutic plasma exchange (TPE) treatment. The patient received TPE with a time interval from plasma transfusion.
A 30-year-old female was evaluated for headaches and bruises on her arms and legs. Laboratory testing revealed thrombocytopenia and anemia. The identification of thrombocytopenia with severe schistocytosis was verified by the analysis of a peripheral blood smear. After confirming a diagnosis of TTP, TPE was performed as therapy. To avoid the complications arising during the previous TPE sessions, we conducted plasma exchange with albumin followed by FFP injection, with a six-hour interval between them. This strategy successfully alleviated the patient's symptoms.
Therapeutic plasma exchange (TPE) with a time interval from plasma transfusion can be successfully used in patients with severe TPE complications.
2. Blombery P, Scully M. Management of thrombotic thrombocytopenic purpura: current perspectives. J Blood Med. 2014;5:15-23.
3. Page EE, Hovinga JAK , Terrell DR, et al. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 2017;1(10): 590-600.
4. Coppo P, Bussel A, Charrier S, et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore). 2003; 82(1):27-38.
5. Rock GA, Shumak KH, Buskard NA, et al. Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenia Purpura. N Engl J Med.1991;325(6):393-7.
6. Coppo P, Bussel A, Adrie C, et al. Early high dose plasma infusion versus plasmapheresis as an emergency treatment of thrombotic microangiopathy: a single center experience. Transfus Apher Sci. 2001; 24(2): 163-164.
7. Escolar G, Páez A, Cid J, et al. Conventional Therapeutic Plasma Exchange Versus Low Volume Plasma Exchange in Chronic Pathologies: Potential Benefit in Alzheimer’s Disease. Plasmatology. 2022; 16.
8. Mahdieh Afzali, Oveisgharan SH, Rajabkhah S, et al. Complications of therapeutic plasma exchange in patients with neurological disorders. Curr J Neurol. 2020; 19(1): 8-12. 9. Bauer PR, Ostermann M, Russell L, et al. Plasma exchange in the intensive care unit: a narrative review. Intensive Care Med. 2022; 48(10):1382–1396.
10. Wang J, Cheng Fu, Niu Y, et al. Therapeutic plasma exchange-free treatment for first-episode TTP: A systematic review. Transfus Apher Sci. 2023; 62(3): 103661.
11. Völker LA, Brinkkoetter PT, Knöbl PN, et al. Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab. J Thromb Haemost. 2020. 18(11): 3061-3066.
12. Chander DP, Loch MM, Cataland SR, et al. Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019; 381(1):92-94.
13. Dabak V, Kuriakose Ph, Raman S, et al. Successful management of a Jehovah's Witness with thrombotic thrombocytopenic purpura unwilling to be treated with therapeutic plasma exchange. J Clin Apher. 2007;22(6):330-2.
14. George JN, Sandler SA, Stankiewicz J, et al. Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah’s Witness experience. Blood Adv. 2017; 1(24): 2161–2165.
15. Tran MH. Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah’s Witness patients: A review of reported cases. Transfus Apher Sci. 2023 ;62(4):103706.
16. Baseri B, Vishwanathan S, Benasher D, et al. Survival of a Jehovah's Witness with thrombotic thrombocytopenic purpura without using plasma: A case report and review of the literature. J Clin Apher. 2019; 34(5): 623-630.
17. Warr TA. Caplacizumab Treatment, without Plasma Exchange, of a Jehovah's Witness with thrombotic thrombocytopenia purpura resulted in rapid and rurable remission: A case report. Blood. 2022; 140 (Supplement 1): 11230–11231.
18. Lim MY, Greenberg CS. Successful management of thrombotic thrombocytopenic purpura in a Jehovah’s Witness: An individualized approach With Joint Decision-Making. J Patient Exp. 2020; 7(1): 8-11.
19. Cardesa-Salzmann TM, Stephan B, Simon A, et al. Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah’s Witness – Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab. Clin Case Rep. 2022; 10(5):e05902.
20. Sukumar S, Lämmle B, Cataland SR. Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management. J Clin Med. 2021; 10(3): 536.
| Files | ||
| Issue | Vol 19 No 1 (2025) | |
| Section | Case Report(s) | |
| DOI | https://doi.org/10.18502/ijhoscr.v19i1.17827 | |
| Keywords | ||
| Plasma exchange; Separate; Thrombotic thrombocytopenic purpura (TTP); Complications | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
